Neoadjuvant immunotherapy improves outcomes in high-risk melanoma patients.

Published Date: 02 Mar 2023

High-risk melanoma patients who received the drug pembrolizumab before or after surgery to remove the cancer had a higher risk of developing melanoma than those who did not have a similar condition that eliminated cancer cells.

Read Full News

Latest News


News All Time

Featured News
Featured Articles
Featured Events
Featured KOL Videos

1.

Losing a reward can affect your motivation and performance.

2.

Biomarker panel offers hope for early pancreatic cancer detection

3.

Nirogacestat is approved by the FDA for treating rare non-cancerous soft tissue sarcomas.

4.

Stop Calling It Cancer; The Alcohol Paradox; Rural Patients Lose Ground in Screening

5.

Vepdegestrant Earns FDA Nod for ESR1-Mutated Breast Cancer


© Copyright 2026 Hidoc Dr. Inc.

Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation
bot